Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsGLP-1 & MetabolicFemale-friendly

Liraglutide Dosing Protocol: GLP-1 Daily Guide

Also known as: Saxenda, Victoza, Daily GLP-1 Agonist

Dose Range
0.6–3 mgResearch range
0Typical research window: 0.6–3 mg4 mg

Studied in published research — not a medical recommendation. Primary protocol (Weight Management Protocol): 0.6-3.0 mg (titrated over weeks), Daily.

Protocol at a Glance
How Often
Daily

Daily

A Typical Run
Ongoing for diabetes/obesity management

Research-reported range; the linked study used a different dose or units. Extensive clinical trials for diabetes and obesity

How It's Taken
Vial

Subcutaneous injection

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

10 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 5 mg in every mL (50 mcg per unit)
0u10u20u30u40u50u
Low end: 0.6 mg12 units
High end: 3 mg60 units

All U-100: 100 units = 1 mL. 16 doses in the vial at the low end (3 doses at the high end).

Track the doses you run

Save Liraglutide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

FDA-Approved MedicationTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Incretin / Dual / Triple Metabolic Receptor Agonist (GLP-1 / GIP / Glucagon / Amylin)
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
FDA-approved pharmaceutical agent in the United States; requires physician prescription for clinical administration.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Liraglutide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza) and obesity (Saxenda). It is a long-acting analog of human GLP-1 with 97% homology.

Mechanisms of Action

  • Activates GLP-1 receptors in pancreas stimulating insulin secretion
  • Suppresses glucagon release reducing hepatic glucose output
  • Slows gastric emptying increasing satiety
  • Acts on hypothalamus reducing appetite

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Weight Management Protocol
reported protocol
0.6-3.0 mg (titrated over weeks)DailyOngoing for diabetes/obesity managementSubcutaneous injectionclinical trial
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (Liraglutide)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

1 Human

Liraglutide 3.0 mg resulted in 8.0% weight loss vs 2.6% with placebo at 56 weeks.

Limitations: Requires daily injection; GI side effects common; weight regain after discontinuation

2015|New England Journal of Medicine
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Black box warning for thyroid C-cell tumors (rodent studies)
  • •Contraindicated in personal/family history of medullary thyroid carcinoma
  • •Risk of pancreatitis - monitor for symptoms
  • •May cause gallbladder disease
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Liraglutide, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.